Aclarion, Inc. (NASDAQ:ACON) Short Interest Update

Aclarion, Inc. (NASDAQ:ACON) was the recipient of a large decline in short interest during the month of January. As of January 31st, there was short interest totalling 13,500 shares, a decline of 99.8% from the January 15th total of 7,750,000 shares. Based on an average daily volume of 335,300 shares, the days-to-cover ratio is presently 0.0 days.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on ACON shares. Maxim Group reiterated a “hold” rating on shares of Aclarion in a report on Friday, December 13th. Ascendiant Capital Markets dropped their target price on shares of Aclarion from $502.50 to $435.50 and set a “buy” rating on the stock in a report on Wednesday, November 27th.

Aclarion Trading Up 11.7 %

Shares of Aclarion stock traded up $0.49 on Wednesday, reaching $4.68. 703,976 shares of the stock were exchanged, compared to its average volume of 800,581. Aclarion has a twelve month low of $3.86 and a twelve month high of $661.63. The business has a 50 day moving average price of $26.47 and a two-hundred day moving average price of $53.26.

About Aclarion

Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software.